Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). AbbVie’s third-quarter 2026 financial results cover the period ended September 30, 2026.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- AbbVie’s third-quarter 2026 financial results cover the period ended September 30, 2026
- Detailed revenue, earnings, guidance and product performance are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $17.404B, up 10.3%, with immunology up 16.3% and neuroscience up 19.4%
- Skyrizi revenue $5.776B and Rinvoq $2.706B, both growing over 22%, offsetting Humira’s 31.2% decline
- GAAP EPS $2.37 versus $0.10, while adjusted EPS reached $3.82, including a $0.11 acquired IPR&D impact
- 2026 adjusted EPS guidance raised to $13.95-$13.99 from $13.76-$13.96, despite $0.69 year-to-date acquisition-related impact
- Apogee acquisition strengthens immunology pipeline, while 2027 dividend increases 5.2% to $1.82 quarterly beginning February 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.